<SEC-DOCUMENT>0000886163-15-000054.txt : 20150429
<SEC-HEADER>0000886163-15-000054.hdr.sgml : 20150429
<ACCEPTANCE-DATETIME>20150429081204
ACCESSION NUMBER:		0000886163-15-000054
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150429
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150429
DATE AS OF CHANGE:		20150429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		15810189

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgndform8-kxpricingvikingi.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>LGNDForm8-K-PricingVikingIPO</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s2C4263CEF434B5FFCF0C0376E3A848D0"></a><div></div><br><div style="line-height:120%;padding-top:5px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): April 29, 2015</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92037</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2C4263CEF434B5FFCF0C0376E3A848D0"></a><div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s673348F6C025F6165CCE0376E3CC5345"></a><div></div><br><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01&#160;&#160;Other Events.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 29, 2015, Ligand Pharmaceuticals Incorporated (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;) partner Viking Therapeutics, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Viking</font><font style="font-family:inherit;font-size:10pt;">&#8221;) announced that it had priced its initial public offering of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share.  According to the announcement, Viking has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the same price to cover over-allotments, if any. Viking expects the shares to begin trading on the Nasdaq Capital Market on April 29, 2015 under the ticker symbol &#8220;VKTX&#8221;.  Viking expects the offering to close on May 4, 2015, subject to the satisfaction of customary closing conditions.</font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laidlaw &amp; Company (UK) Ltd. is acting as the sole book-running manager for the offering.  Feltl and Company, Inc. is serving as co-manager for the offering.</font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The offering is being made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Laidlaw &amp; Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, New York, NY 10036, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.  A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on April 28, 2015.  </font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders and has licensed assets from the Company.</font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has issued a press release related to the offering, a copy of which is filed as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated April 29, 2015.</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s673348F6C025F6165CCE0376E3CC5345"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="45%"></td><td width="5%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: April 29, 2015</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, General Counsel and Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s673348F6C025F6165CCE0376E3CC5345"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated April 29, 2015.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vktxipopricing_42915.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>VKTXIPOPricing_42915</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s88F540B80E8D0445E8220374E5DDDF3A"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:left;"><img src="vktxipopricing42915v6_image1.gif" style="height:38px;width:109px;"></div><div style="line-height:120%;text-align:left;text-indent:160px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:588px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="360px"></td><td width="228px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LHA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Todd Pettingill, Sr. Manager, CorpDev and IR</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bruce Voss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@ligand.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 550-7500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(310) 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Partner Viking Therapeutics Announces Pricing of Initial Public Offering</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO, CA (April 29, 2015) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:11pt;">&#32;partner Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that it has priced its initial public offering of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share.</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Viking has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the same price to cover over-allotments, if any. Viking expects the shares to begin trading on the Nasdaq Capital Market on April 29, 2015 under the ticker symbol &#8220;VKTX&#8221;.  Viking expects the offering to close on May 4, 2015, subject to the satisfaction of customary closing conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Laidlaw &amp; Company (UK) Ltd. is acting as the sole book-running manager for the offering. Feltl and Company, Inc. is serving as co-manager for the offering.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The offering is being made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Laidlaw &amp; Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, New York, NY 10036, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.  A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on April 28, 2015. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand invested $9 million in the offering. Ligand will issue an additional press release once the transaction has closed. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Viking Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients&#8217; lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. Viking&#8217;s clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, entering Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy and lipid disorders, as well as two earlier-stage programs targeting metabolic diseases and anemia. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous </font></div><br><div></div><hr style="page-break-after:always"><a name="s88F540B80E8D0445E8220374E5DDDF3A"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer&#8217;s disease, dyslipidemia, anemia, asthma and osteoporosis.  Ligand&#8217;s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly &amp; Co.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>vktxipopricing42915v6_image1.gif
<TEXT>
begin 644 vktxipopricing42915v6_image1.gif
M1TE&.#EA^P!9`/<```````````````$!`4!`ID%!I4%!HTE)FTQ,C4]/DU55
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MO<W-S<_/S]S<W-S<W-S<W"'Y!`$`````+`````#[`%D`0`C^``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$C1(3=KJE1A$:)*R#^%@%RY.F)#U0T`(E.FW%.QI<N7
M,&/*G#E1E<J4JA3N">5*R!%7)V^NI$FT(IRC2).R*<JTZ4R;0G-&%"J2)5%G
M5%T!:WBA#Y>L8$6.4"4`(IVP:%5*H\?P[,T^!/^I&I'V9J@K%0$)J7MS#Y>!
M4&]*A9C5*DVL5+<>#*Q2%;R'P$Y0%8+0VHB2%RCVR3H*H5NP)[`XW`-6=$(J
M624_5"4Y[."'A8LB%JJXX$^A?3X2I@JW:9&LI@M^;ESQ-NZ#FX4>.=F2,4Z)
ML:]FK7UP#VF^:5\?O,!W+Y;K?(/^$QS^G.(-L`;)I]3STKE([0VC'YYN<+9*
MO$SA9>T=\3=5\0.IYPI\#YV7%7*<+4"1`.Z]!QUV$+H"(`#VJ41=05Q8%V%=
MJA647%9"Z('%7P#<@$4?`@)WD(`$.F0@50K=\"%8&NW1QR@-IN0,3X(YY2-!
MX#7&5DL?T/?CD4@FJ61$(17F3$2A!"G4DE16:>65!=%S41\V<C3"""?0-<IF
M>K@"2&98IJDF3/2\PX4SYW"SYIQTUKD:52U*XPH`';G2!SVNM""?G3"QP<8D
M1TT2"1L>$.HH1`VVJ-"@CU+$1B1)(55)HY5VBE"D#PIEV$P5IG1A065F-8(>
M>]P``3W^YPSABI13)L1C5G3@*`T6TF1$Q8Q&KHB;$'MEI4<HHXS"ET.1H77"
MC2BV!J&D"5$:4ZDBG0I`DS=U%A&V7`Q9%#!9/9D>57L`0I&J'QQ$CZ!"C<!!
M17KB&6I?L@5;D*Q9B:L0,%^)6E9#-^@E[88J30@`BQ6]6"M!5AC;GKU3H9MO
M8@>)$[!*?5R@1XHWA>910ZA1U<(Y_:EX;E0-HV=0I`HV1_%NHEY,FT$+Y.C*
M"&/VT0<6U@`#C!#<<./,.Q6@Z9"R0G'!G$.N;"R4P@R;Y[)!\!S<6`P."5"O
M:Q(!B_!^]>D;H-@#VO`0%];0RK%!)4=XPAYREJBUA,*R;/7^@0UQPS2$@@XL
MT*WE>;I0*'>[0L5+5V2EMN&01QZ3`CJ/G1(5+4BN^>:<=UXIJ`>=HXIU/F-!
M@A#2),Z?YZRW7A#H!G$S`A:J]+%`*-84:['KO+L..VR[]UY0IIE*(OR<OT,=
M_/$"L4$\4DLQGV;R\2U/:E^K.R3#KF%)IL<[+PD`"&DVA+5'"WOH8:Y#+6B$
MT_H%W;!'W#>-T(<J)+(9L>[=4N&,OP*A'D.L!1-L:64AXJ"?Y;`0@85P`&V6
MDQ``A7,<`(2B<G71ED(@B)VY\6EFP*N9=#"&$+?Y27`(N8$"4R*-A)1/)538
MB4-"`<$1/(V"=1D%?JI#EZRH:R'^'!Q0S`YR(KY0"R$$?(D!M14*%U#EAW<2
MBK>8DI4C3'!A8#G"XB!BC:L9Q(1">$Q$3.B@BHEP/B0LB`DEP@V373$FB'MB
MWGJTKJQL\75V=(D`%Y)$ERP1(81+2?86(K6;5(0>-P`&EVB7D4:JHEE3FR-Q
M]@:C+/7P8179XZ2L=RVS$:2-8`'$%>&!/\Z\<2#_L,(E(W@3JH$P(@XS)`[U
M)C-:AA!?([S90=[!2EPJ!)1V;%=#_!/)E=%Q(K%4B4$NR+=:'O.6*AF53/Y8
MD'^\<)(%"<41@,$-.M1`:1%!&QU.F1!BME*2A9-(,E-2'4]&1)/5XF0!/<D_
MG*"L*,;^.:=$N*7/66)3G5XD"!8X,Q$])*Z,-+L),"[`T(8Z]*$09>@5J9FE
M("),4/`C2(Y(PQ!>IL65MH1E0,=3R)L<02&A""2-[M7+F]QQ(!1=9CU;^C:"
MW(B5)]###>X&TF>*M)D)P2!?0C&XD#I$"%B@@E*7RM2F.O6I5`#&#04B/MJU
MH`6C2-<$5^B*CU7D'"H5B3@`J9&2WD0(!/AB'ZZJBC$-D2`AP5$+Z$"%[[7$
M%6.ZJ@UL]-:&;(\U8(EJW0P2$CJT#S50;%V#I#D1!O%&>I"U$[S>,M4QYC&R
MF)W30--"A_DU$A!ZV,PHS*H2.E`FLZBM$PU;.@(9IO:UL(W^+9;0UD*$D$L5
MY\B',VQ$3MGZ-DE[W%'.`,&-V@'B5ZZ0UI@4]MOFTF2/6`@%@ZRCAS9N]HS.
MS>YS7VE3])7E@JKP*':U2]Z)&35+W`C%/5$B3^9)P@-P\$`6RLL4>"*QO;RK
M!**>-U_ZRL2^!^FCZ^#[/#A$PK__Y>X`\>LZYQ4X>@@VKT^K-][C8:K`<(@P
M3`!L$`'3B1Y6Z&*O``$T8)Q248:*A`<,-8F&_",40NC&'C*BN/EQHZ]-"046
MK."ST=%AL$2Y@#AH]ZO1A>*4'"Z(ARFB'Z&<X'$-L0$52(LG_U&$!#>-T`BH
M0%2259(@,M##*L%"!YVZA!ZEK$O^'S*:9((L>2(Q18@,_F:Y!C(D!H!M*1:`
MC$X_#:3)"%.%-28201L\KLT#>;-$XIS-NAR!#E1>"0J_2-,)C^<XXFBI#2J;
MD*]%<&Z(%HBBO^5.@0#BH%0@04(``4'\)01MJHCA*8<`##J_)2'JF3)50N,,
M80*@`\[X3ECX?)`8<%60>Y`!04B`A5$<5,%\9'!%&"V0W?)FT@B)`-I&`4XW
MX\05O37($/*IDD'WV<EK60@5R*T23@^D!K9.R0A.JQ#NU.6(`98V1:@-@'@/
M*)Q4J:V[PHW25%D:BS32H+O`,LB!<&.RMX;('IRX4C/Z\GII)$A8P\4DH!(%
M+"4XMTC^&KX0>K`HK?FFRDLE;D)\=UC?<':GVYBK$!)07"4M(/B^071NQCX$
M@ADU]4@A0@]8LW0HN53H06:*5XF02R@VP+9,S)FP<[O<MCX\B,%ODMB:0'N3
M%9YGQ@<B7I6<@-C1%LK*:4+UE/3TGU`:NH"@G,FOQS/L2BQU5EH`/H<TZ.Q0
MLD+M6O!LM+P]G3_]\D!(H#H)PYW"%Y]FJ0%PW;/VEIE4,?="BF#1#1T>H0#U
M.`"`>7!(V?V^>/?CY#_(\(S8:$"PSXHJNFX0>AR[EY__-R4Q*9`4D=STYTU[
MY#LY=H(8$&$S9DCEI>@G;J`<(6T72>ZO?I!UBL0@UU2Z'D_^G_+ABUV7+X?Z
MAD9A!88(H-5==DCT\6;,QQ=HI!\P*WNV'WRP>S_OQ:?\U(84`>N$8NM[D"Q<
M4@,2)WL2L7[3US*BUV^[=E+.Y'["%TTVHWUP115H%Q,"X&][<H`JXT^(!Q'6
MMX$%<6PT1S!A17V)!G.+YDG+)Q)K)WG<=Q`(:'4*J'@.=U"TYW<5EU`2F'06
M4C94,0K1110A*!$CTH&75G\,482+$4H1D3I@8W$]B$;@IU$1Y$0C`&.\T@?N
M5E0JUS5YAH0!$H,I-'0"049"``$,<0$M2(;>1A5T$(=R.(=T6(=Q"&-`6(7&
MUWD;$AJT1V4GH`IO1`]ZH(']E(3^I;>$9GB&KK$'JD80"W!\N:*$J%=I*9%^
M,+5ZSL!TO12(!5$!0C4K9)1<4'B(8TB),;*(`@$P+44%**-2*"@0A1=!=)"'
M%%@0SI!]*9%5:Y81TI`^UD$%&4$[D38@F`@`5K!U$:(1=E-,'@AZB<=[)31F
MV$$:X@*+T#&+8S-(=)`X]#80"^!O-C!6$F$#814H$R0C$,(J!&%O9X4@J)@0
M69-_"%%<VBA(&F`08O-[FA,!=1!P+A$6"W$.]S,Z>^`,7')DK\4-!<DE]V,-
MC]A<;N-S$2$`896#&J9A]$"-/?$2%9`XFI>1(@D`[IB(+N8X.C>2SJ6!JH!C
M4'-0QZ@VDAHF.F`1@*HP+PKQ`4\'%J'0A3+I7X!BB5(4=#\YDO_0*Y:X*C%9
1E$Q)#\*&?*[0`4SI*`$!`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
